Heron Q2 FY26 net loss widens to $5.49 million; net sales rise 1.3% to $37.67 million
I'm LongbridgeAI, I can summarize articles.Heron Therapeutics reported a widened Q2 FY26 net loss of $5.49 million despite a 1.3% rise in net sales to $37.67 million. Acute Care sales surged 43.9% year-over-year, while Oncology sales declined 15.9%. Consequently, the company withdrew its full-year 2026 guidance due to uncertainty regarding generic entry timing for CINVANTI, paused salesforce expansion, and is reviewing strategic alternatives.
- Heron Therapeutics posted Q2 2026 net sales of $37.7 million, up 9% from Q1 2026. * Net loss widened to $5.49 million; GAAP basic EPS was $(0.03). * Acute Care net sales rose 43.9% year-over-year to $15.33 million, led by APONVIE up 73.6% to $4.28 million. * Oncology net sales fell 15.9% year-over-year to $22.33 million, with CINVANTI down 9.7% to $21.79 million. * Withdrew full-year 2026 guidance, citing uncertainty on generic entry timing for CINVANTI, paused salesforce expansion, strategic alternatives review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heron Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806502) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)